What the buyer needs
AI summaryBARDA seeks contractors to produce vaccines, antigens, and adjuvants for pandemic influenza preparedness and response. The program also supports regulatory decisions and manufacturing readiness. Offerors must demonstrate successful experience in manufacturing influenza vaccines. This can be shown by holding a U.S. influenza vaccine license or by submitting a Biologics License Application (BLA). Full solicitation details and proposal submission instructions are available in attachments 01-21.
Incumbent and award research
Likely prior awards for this requirement
Likely matchAwarded by the same buying office (75A501) with descriptions matching "vaccine", performed in DC. The notice does not name its current contract, so confirm before relying on it.
| Vendor and award | Value | Ends |
|---|---|---|
| ADVANCED TECHNOLOGY INTERNATIONAL75A50124F61008 · OT TASK ORDER 8-RAPID PANDEMIC INFLUENZA AND EMERGING INFECTIOUS DISEASE VACCINE DEVELOPME | $563.7M | Sep 30, 2036 |
Market context
Awards in the same category (Research and Development in Biotechnology (except Nanobiotechnology)). This is not this requirement's award history.
Recent similar awards: Department of Health and Human Services, NAICS 541714, performed in DC
| Vendor and award | Value | Ends |
|---|---|---|
| ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)75A50123C00010 · THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE | $163.1M | Sep 30, 2030 |
| MELINTA THERAPEUTICS, LLC75A50123C00022 · ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TRE | $47.5M | Jun 30, 2030 |
| ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)75A50119C00055 · THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBU | $145.4M | Sep 30, 2027 |
| BATTELLE MEMORIAL INSTITUTE75A50125F61004 · USE OF A HUMAN-RELEVANT SMALL ANIMAL MODEL OF SULFUR MUSTARD (SM)-INDUCED INHALATION INJUR | $7.6M | Mar 28, 2027 |
| INFLO MEDICAL INC75A50124C00019 · THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO IMPROVE THE SAFETY METRICS FOR EXTRACORPOREAL | $747.4K | Jun 21, 2026 |
Top vendors in this category: Department of Health and Human Services, NAICS 541714, since Oct 1, 2024
1,152 contract awards in this NAICS over the period.
- 1. ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)$336.6M
- 2. AMGEN USA INC$215.9M
- 3. START2 GROUP, INC.$194.3M
- 4. SHIONOGI INC$156.1M
- 5. MAPP BIOPHARMACEUTICAL, INC.$133.1M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.